Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN trimmed its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 38.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 40,732 shares of the biotechnology company's stock after selling 25,925 shares during the period. Wells Fargo & Company MN owned 0.06% of Blueprint Medicines worth $3,553,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. R Squared Ltd acquired a new position in Blueprint Medicines in the fourth quarter valued at $51,000. Headlands Technologies LLC purchased a new position in shares of Blueprint Medicines in the 4th quarter worth about $65,000. Asset Management One Co. Ltd. acquired a new position in shares of Blueprint Medicines in the 4th quarter valued at about $88,000. Van ECK Associates Corp grew its holdings in shares of Blueprint Medicines by 48.2% during the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock worth $97,000 after purchasing an additional 363 shares during the period. Finally, Venturi Wealth Management LLC acquired a new stake in Blueprint Medicines during the 4th quarter worth approximately $131,000.

Insiders Place Their Bets

In other Blueprint Medicines news, insider Ariel Hurley sold 3,203 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $92.62, for a total value of $296,661.86. Following the transaction, the insider now owns 18,270 shares of the company's stock, valued at $1,692,167.40. This trade represents a 14.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $95.02, for a total value of $216,075.48. Following the completion of the transaction, the chief operating officer now owns 69,266 shares of the company's stock, valued at approximately $6,581,655.32. The trade was a 3.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.21% of the stock is owned by corporate insiders.

Blueprint Medicines Stock Up 1.0 %

Blueprint Medicines stock traded up $0.85 during midday trading on Monday, hitting $88.51. The stock had a trading volume of 786,733 shares, compared to its average volume of 770,079. The business has a fifty day moving average price of $87.46 and a 200 day moving average price of $93.18. Blueprint Medicines Co. has a 12 month low of $73.04 and a 12 month high of $121.90. The stock has a market cap of $5.66 billion, a P/E ratio of -81.95 and a beta of 0.75. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Research analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Analyst Ratings Changes

BPMC has been the subject of several research reports. JMP Securities reiterated a "market outperform" rating and set a $125.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 14th. JPMorgan Chase & Co. upped their price target on shares of Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. StockNews.com lowered Blueprint Medicines from a "hold" rating to a "sell" rating in a research report on Monday, March 3rd. Jefferies Financial Group started coverage on Blueprint Medicines in a research report on Monday, March 17th. They issued a "buy" rating and a $135.00 target price for the company. Finally, Stephens reiterated an "overweight" rating and issued a $140.00 target price on shares of Blueprint Medicines in a research note on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $124.53.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.